Alternatively, RASSF1A promoter methylation was positive in 23.3% of the patients, closely equivalent to what was detected in Europeans (20.0%) (15), but lower that what reported in saliva obtained from HNSCC patients in Australians (50.0%) (8). This evidence concerns the gene RASSF1 and head and neck squamous cell carcinoma.